Chief Medical Officer Dan Karlin said the company’s recent Phase III results for DT120 showed statistically significant improvements in generalized anxiety disorder, or GAD, and major depressive ...

Definium Therapeutics (NASDAQ:DFTX) reported positive top-line results from Panorama, its second Phase III study of DT120 ODT ...

The "effort" shaken by generative AI and the value of artIn the previous article, I discussed how humans may be looking not ...

Vor Biopharma Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a dual-ta ...

Good morning, and welcome to the Kyverna Therapeutics Conference Call. [Operator Instructions] Please note, this call is being recorded. I would now like to introduce Jessica Serra, Head of Investor ...

A simple blood draw that reads chemical tags on DNA shed by tumors has delivered a strikingly better performance than the ...

In UI (User Interface) design, the idea that dark mode—where the background is darkened and text and information are displayed brightly—is simply 'cooler because it's darker' is generally not a ...

The Stockholm stock market was trading slightly lower around midday on Friday. The market is thus taking a breather after two ...

Vor Biopharma is advancing telitacicept globally, leveraging strong Chinese clinical evidence and a robust liquidity position. Read why VOR stock is a buy.

The White House has labeled critics terrorists, attributed violence to a left-wing conspiracy and investigated unions, nonprofits and other groups in a battle over free speech.

BACKGROUND: The extravascular implantable cardioverter defibrillator (EV-ICD) was developed to provide defibrillation and antitachycardia pacing therapy without the need for intravascular lead ...

Quantum batteries have moved from a theoretical curiosity to one of the most actively pursued ideas in quantum thermodynamics, promising charging speeds and power densities that no electrochemical ...